The coronavirus disease 2019 (COVID-19) pandemic seems to be at its end. During the first outbreak, alfa was the dominant variant, and in the two following years, delta was the dominant variant. Questions remain about the prevalence and severity of post-COVID syndrome (PCS). We compared the medium-term outcomes of a selected group of patients considered at high risk for PCS: hospitalized patients with severe COVID-19 infection who presented clinical evidence of the acute onset of venous thromboembolism. Weighted Cox regression was used to estimate the adjusted hazard ratios for the risk of early and medium-term complications and quality of life (QoL) in COVID-19 patients developing acute venous thrombo-embolism according to the period of admission to the hospital. The primary outcome was the modification of QoL at a median follow-up of 24 months in patients hospitalized for COVID-19. The secondary outcome was the modification of QoL related to COVID-19 severity. The absolute risk of mortality for hospitalized COVID-19 patients was higher during the first outbreak (risk difference, 19% [95% confidence interval [CI], 16–22%]). Patients with acute onset of thromboembolism during the first outbreak had increased mortality, hospital stay, and need for intensive care unit treatment (p < 0.01). In patients who suffered from severe COVID-19 infection and thromboembolism in the following 2 years, symptoms during follow-up were less common and milder (risk difference 45% [95% CI, 40–52%]. In total, 19 patients were alive at 24 months follow-up: 12 patients (63%) reported important physical symptoms and 10 patients (52%) relevant emotional/mental symptoms. All patients reported reduced QoL in comparison with the preinfection time; in 15 patients (79%), the reduced QoL limited significantly their social and work activities. All patients reported permanent worsening of QoL after discharge from the hospital. Comparing the three different February to April interval years (2020, 2021, and 2022), patients reported a somewhat worse perception of health condition in comparison with the preinfection time, respectively, in 100, 79, and 56% respectively. The findings of our study show reduced prevalence and severity of PCS in the last 2 years. Less virulent variants, herd immunity, and vaccination may played a significant role.

2019 年冠状病毒病 (COVID-19) 疫情似乎已经结束。在第一次爆发期间，α 是主要变种，在接下来的两年中，δ 是主要变种。关于新冠肺炎后综合症 (PCS) 的患病率和严重程度仍存在疑问。我们比较了一组被认为具有 PCS 高风险的患者的中期结果：患有严重 COVID-19 感染的住院患者，他们提供了静脉血栓栓塞急性发作的临床证据。使用加权Cox回归来估计根据入院时间发生急性静脉血栓栓塞的COVID-19患者的早中期并发症风险和生活质量（QoL）的调整后风险比。主要结局是因 COVID-19 住院患者中位随访 24 个月后生活质量的变化。次要结果是与 COVID-19 严重程度相关的生活质量的改变。首次爆发期间住院的 COVID-19 患者的绝对死亡风险较高（风险差异，19% [95% 置信区间 [CI]，16-22%]）。首次暴发期间血栓栓塞急性发作的患者死亡率、住院时间和重症监护病房治疗需求增加（p  < 0.01）。在随后 2 年内出现严重 COVID-19 感染并发生血栓栓塞的患者中，随访期间症状较少见且较轻（风险差异 45% [95% CI，40–52%]。总共 19 名患者24 个月随访时存活：12 名患者 (63%) 报告重要的身体症状，10 名患者 (52%) 报告相关情绪/精神症状。所有患者均报告与感染前相比生活质量下降；其中 15 名患者 (79%) ，降低的生活质量显着限制了他们的社交和工作活动。所有患者在出院后都报告生活质量永久性恶化。比较三个不同的二月至四月间隔年份（2020年、2021年和2022年），患者报告的生活质量感知稍差与感染前相比，健康状况分别下降了 100%、79% 和 56%。我们的研究结果显示，过去 2 年 PCS 的患病率和严重程度有所下降。毒性较小的变异、群体免疫和疫苗接种可能会发挥作用发挥着重要作用。